Menstrual Discomfort: Causes, Types, Relief, and When to Seek Help
Menstrual discomfort is one of the most common experiences that the majority of people with menstrual cycles are likely to face. It can range from mil...
Dr. Reddy’s Laboratories Ltd., announced the launch of FXR™, a therapeutic equivalent generic version of Ocaliva® (obeticholic acid) in India, indicated for the treatment of Primary Biliary Cholangitis (PBC), in combination with Ursodeoxycholic Acid (UDCA) or as monotherapy in adults. Commenting on the launch, M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s Laboratories said, “We are excited to be the first generic company to market Obeticholic Acid in India. The launch of FXR™, the first-in-class Farnesoid X receptor agonist represents Dr. Reddy’s expertise to accelerate access to affordable alternatives for complex products. FXR™ will be an important addition to our Hepatology portfolio.” Dr. Reddy’s FXR™ is available in strengths of 5mg and 10mg tablets. PBC, is a rare chronic autoimmune disease, characterized by the destruction of small bile ducts in the liver. The only approved treatment for PBC in India as of today is UDCA, which was approved almost two decades ago. *Though considered as a first-line treatment for PBC, up to 40% of the patients do not respond to UDCA treatment, leaving many PBC patients with no approved treatment option. In 2016, Obeticholic acid received accelerated approval for the treatment of PBC as an ‘orphan drug’ in the U.S.
Menstrual discomfort is one of the most common experiences that the majority of people with menstrual cycles are likely to face. It can range from mil...
Conjunctivitis is commonly known as pink eye, and it is an eye condition that includes inflammation of the conjunctiva, the thin clear tissue that lin...
Travelling is one of the best ways to explore new places, cultures, and experiences. But at times, it can pose some challenges to staying healthy and ...